CStone Submits Ayvakit for Approval in Taiwan for PDGFRA Exon 18-Mutated Stomach Cancer

Mar 27, 2020

|

NEW YORK – CStone Pharmaceuticals said on Friday that it submitted a new drug application for its precision cancer drug avapritinib (Ayvakit) to the Taiwan Food and Drug Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

CStone Submits Ayvakit for Approval in Taiwan for PDGFRA Exon 18-Mutated Stomach Cancer

To read the full story....

Breaking News

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

Takeda Scores First-Line FDA Approval for Alunbrig in ALK-Positive Metastatic Lung Cancer

Invivoscribe Receives Supplemental Approval for AML Kit

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

Featured White Papers

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

What's Popular?

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Janssen Antibody Produces Durable Responses in Lung Cancer Subset With Poor Prognosis

Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice

Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

Sponsorships